Home » Stocks » THTX

Theratechnologies Inc. (THTX)

Stock Price: $3.51 USD 0.00 (0.00%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 333.38M
Revenue (ttm) 50.59M
Net Income (ttm) -18.50M
Shares Out 94.60M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE 55.87
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $3.51
Previous Close $3.51
Change ($) 0.00
Change (%) 0.00%
Day's Open 3.50
Day's Range 3.40 - 3.55
Day's Volume 102,773
52-Week Range 1.68 - 4.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MONTREAL, May 13, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization o...

3 days ago - GlobeNewsWire

MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization...

1 month ago - GlobeNewsWire

MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovati...

1 month ago - GlobeNewsWire

MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovati...

1 month ago - GlobeNewsWire

TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone

1 month ago - GlobeNewsWire

MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the dev...

1 month ago - GlobeNewsWire

MONTREAL, March 24, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovati...

1 month ago - GlobeNewsWire

Theratechnologies (THTX) has moved higher as of late, but there could definitely be trouble on the horizon for this company

1 month ago - Zacks Investment Research

Data presented at ENDO 2021 Data presented at ENDO 2021

1 month ago - GlobeNewsWire

MONTREAL, March 10, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovati...

2 months ago - GlobeNewsWire

MONTREAL, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

2 months ago - GlobeNewsWire

Record Q4 and FY2020 revenues of $19.1 million and $66.1 million, respectively Record Q4 and FY2020 revenues of $19.1 million and $66.1 million, respectively

2 months ago - GlobeNewsWire

MONTREAL, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovativ...

3 months ago - GlobeNewsWire

The FDA has designated Fast Track status to Theratechnologies Inc's (NASDAQ: THTX) TH1902 as a single agent for treating patients with sortilin positive recurrent advanced solid tumors that are refracto...

3 months ago - Benzinga

MONTREAL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

3 months ago - GlobeNewsWire

MONTREAL, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerciali...

3 months ago - GlobeNewsWire

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

3 months ago - GlobeNewsWire

MONTREAL, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

4 months ago - GlobeNewsWire

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

4 months ago - GlobeNewsWire

I n addition to ovarian and triple-negative breast cancers , TH1902 shows pre-clinical in vivo efficacy in colorectal, pancreatic, melanoma and endometrial cancers

5 months ago - GlobeNewsWire

MONTREAL, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

5 months ago - GlobeNewsWire

MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

6 months ago - GlobeNewsWire

MONTREAL, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

6 months ago - GlobeNewsWire

MONTREAL, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

6 months ago - GlobeNewsWire

MONTREAL, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

6 months ago - GlobeNewsWire

MONTREAL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

7 months ago - GlobeNewsWire

MONTREAL, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

7 months ago - GlobeNewsWire

MONTREAL, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended Augus...

7 months ago - GlobeNewsWire

MONTREAL, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovati...

7 months ago - GlobeNewsWire

MONTREAL, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innova...

7 months ago - GlobeNewsWire

Phase 3 protocol to be filed in Q4 2020; trial expected to begin early 2021

8 months ago - GlobeNewsWire

First commercial launch in Europe

8 months ago - GlobeNewsWire

MONTREAL, July 30, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that Philippe Dubuc, the ...

9 months ago - GlobeNewsWire

Theratechnologies NASH Data And Other News: The Good, Bad And Ugly Of Biopharma

9 months ago - Seeking Alpha

Sub-analysis of MGH study helps better demonstrate how tesamorelin reduces liver fat

9 months ago - GlobeNewsWire

MONTREAL, July 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today held its annual meeting of sharehol...

10 months ago - GlobeNewsWire

Theratechnologies Inc. (THTX) CEO Paul Lévesque on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

-Total product revenues of $17.2M, a 10% increase compared to Q2 2019 and 9% increase compared to Q1 2020-

10 months ago - GlobeNewsWire

sBLA expected to be filed in early 2022

10 months ago - GlobeNewsWire

MONTREAL, July 06, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that data presente...

10 months ago - GlobeNewsWire

Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptor

10 months ago - GlobeNewsWire

Significant inhibition of vasculogenic mimicry observed with TH1902 and TH1904

1 year ago - GlobeNewsWire

MONTREAL, April 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc., or Theratechnologies (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that Paul Lévesque, th...

1 year ago - GlobeNewsWire

Theratechnologies Inc. (THTX) CEO Paul Lévesque on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

New sub-analysis of MGH Study presented at CROI 2020 New sub-analysis of MGH Study presented at CROI 2020

1 year ago - GlobeNewsWire

Theratechnologies Inc. (THTX) CEO Luc Tanguay on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

MONTREAL, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce the signing of lon...

1 year ago - GlobeNewsWire

MONTREAL, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today provided preliminary revenue estima...

1 year ago - GlobeNewsWire

About THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystr... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1993
CEO
Paul Levesque
Employees
54
Stock Exchange
NASDAQ
Ticker Symbol
THTX
Full Company Profile

Financial Performance

In 2020, THTX's revenue was 66.05 million, an increase of 4.49% compared to the previous year's 63.22 million. Losses were -22.67 million, 81.4% more than in 2019.

Financial numbers in millions CAD.
Financial Statements